VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
STIMNeuronetics, Inc.
$1.23$86M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

STIM logoNeuronetics, Inc.(STIM)Earnings, Financials & Key Ratios

STIM•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryDiagnostic Imaging Systems and Services
AboutNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Show more
  • Revenue$149M+99.2%
  • EBITDA-$28M+13.9%
  • Net Income-$39M+10.8%
  • EPS (Diluted)-0.59+57.2%
  • Gross Margin48.48%-33.0%
  • EBITDA Margin-18.75%+56.8%
  • Operating Margin-21.08%+54.3%
  • Net Margin-26.15%+55.2%
  • ROE-134.39%-1.4%

STIM Key Insights

Neuronetics, Inc. (STIM) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 24.8%
  • ✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

  • ✗High debt to equity ratio of 3.4x
  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 20 (bottom 20%)
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when STIM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

STIM Price & Volume

Neuronetics, Inc. (STIM) stock price & volume — 10-year historical chart

Loading chart...

STIM Growth Metrics

Neuronetics, Inc. (STIM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years24.81%
3 Years31.76%
TTM69.52%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM23.49%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM58.78%

Return on Capital

10 Years-40.44%
5 Years-31.72%
3 Years-32.04%
Last Year-28.49%

STIM Recent Earnings

Neuronetics, Inc. (STIM) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$0.16+5.9%
$0.17
Rev
$34M+0.8%
$34M
Q2 2026
Mar 17, 2026
Metric
Actual
Est
EPS
$0.10+16.7%
$0.12
Rev
$42M+2.7%
$41M
Q4 2025
Nov 4, 2025
Metric
Actual
Est
EPS
$0.13-8.3%
$0.12
Rev
$37M-1.5%
$38M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.15-87.5%
$0.08
Rev
$38M+0.7%
$38M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$0.16vs $0.17+5.9%
$34Mvs $34M+0.8%
Q2 2026Mar 17, 2026
$0.10vs $0.12+16.7%
$42Mvs $41M+2.7%
Q4 2025Nov 4, 2025
$0.13vs $0.12-8.3%
$37Mvs $38M-1.5%
Q3 2025Aug 5, 2025
$0.15vs $0.08-87.5%
$38Mvs $38M+0.7%
Based on last 12 quarters of dataView full earnings history →

STIM Peer Comparison

Neuronetics, Inc. (STIM) competitors in Diagnostic Imaging Systems and Services — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
ELMD logoELMDElectromed, Inc.Direct Competitor320.27M38.6844.9816.97%14.08%22.14%0.00
NVCR logoNVCRNovoCure LimitedDirect Competitor1.62B14.28-11.708.28%-25.66%-50.82%0.85
ABSI logoABSIAbsci CorporationProduct Competitor1.16B7.41-8.82-38.24%-64.51%-63.58%0.03
LIVN logoLIVNLivaNova PLCProduct Competitor4.31B78.50-17.6410.74%7.47%9.13%0.39
INVA logoINVAInnoviva, Inc.Product Competitor1.66B22.496.8218.52%118.91%47.59%0.23
GKOS logoGKOSGlaukos CorporationProduct Competitor7.65B130.68-39.8432.33%-34.34%-26.46%0.21
ABT logoABTAbbott LaboratoriesSupply Chain153.68B88.3811.574.59%31.88%27.26%0.32
MDT logoMDTMedtronic plcSupply Chain101.86B79.3421.983.62%13%9.49%0.59

Compare STIM vs Peers

Neuronetics, Inc. (STIM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ELMD

Most directly comparable listed peer for STIM.

Scale Benchmark

vs ABT

Larger-name benchmark to compare STIM against a more recognizable public peer.

Peer Set

Compare Top 5

vs ELMD, NVCR, ABSI, LIVN

STIM Income Statement

Neuronetics, Inc. (STIM) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
40.43M52.78M62.66M49.24M55.31M65.21M71.35M74.89M149.16M151.64M
Revenue Growth %
18.13%30.53%18.72%-21.41%12.32%17.89%9.42%4.96%99.17%69.52%
Cost of Goods Sold
9.63M12.45M15.39M11.55M11.65M15.48M19.64M20.73M76.85M78.91M
COGS % of Revenue
23.82%23.58%24.56%23.46%21.07%23.74%27.53%27.68%51.52%-
Gross Profit
30.8M▲ 0%
40.33M▲ 30.9%
47.27M▲ 17.2%
37.69M▼ 20.3%
43.66M▲ 15.8%
49.72M▲ 13.9%
51.7M▲ 4.0%
54.16M▲ 4.8%
72.31M▲ 33.5%
72.72M▲ 0%
Gross Margin %
76.18%76.42%75.44%76.54%78.93%76.26%72.47%72.32%48.48%47.96%
Gross Profit Growth %
11.57%30.93%17.2%-20.26%15.84%13.89%3.99%4.75%33.51%-
Operating Expenses
44.41M60.16M74.2M60M71.22M84.83M82.26M88.72M103.74M102.14M
OpEx % of Revenue
109.83%114%118.42%121.84%128.77%130.1%115.29%118.47%69.55%-
Selling, General & Admin
36.47M51.93M60.45M50.8M63.3M75.5M72.74M75.95M97.16M95.81M
SG&A % of Revenue
90.2%98.4%96.48%103.16%114.44%115.78%101.96%101.42%65.14%-
Research & Development
7.94M8.23M13.75M9.2M7.92M9.34M9.52M12.77M6.58M6.33M
R&D % of Revenue
19.63%15.6%21.94%18.68%14.32%14.32%13.34%17.05%4.41%-
Other Operating Expenses
357K-575K00000000
Operating Income
-13.61M▲ 0%
-19.83M▼ 45.8%
-26.93M▼ 35.8%
-22.31M▲ 17.2%
-27.56M▼ 23.6%
-35.11M▼ 27.4%
-30.55M▲ 13.0%
-34.56M▼ 13.1%
-31.44M▲ 9.0%
-29.42M▲ 0%
Operating Margin %
-33.66%-37.58%-42.98%-45.3%-49.83%-53.85%-42.82%-46.15%-21.08%-19.4%
Operating Income Growth %
-45.74%-45.75%-35.78%17.16%-23.56%-27.38%12.98%-13.12%9.05%-
EBITDA
-12.94M-18.95M-25.86M-21.37M-26.5M-33.46M-28.55M-32.49M-27.97M-26.86M
EBITDA Margin %
-31.99%-35.91%-41.28%-43.39%-47.92%-51.32%-40.01%-43.38%-18.75%-17.72%
EBITDA Growth %
-49.3%-46.52%-36.48%17.39%-24.04%-26.26%14.69%-13.81%13.91%25.99%
D&A (Non-Cash Add-back)
673K882K1.06M941K1.06M1.65M2.01M2.07M3.46M2.55M
EBIT
-13.25M-20.41M-28.26M-26.83M-27.87M-33.61M-24.77M-36.44M-31.44M-20.48M
Net Interest Income
-2.81M-3.69M-3.69M-4.52M-3.3M-3.6M-5.4M-7.3M-8.41M-6.15M
Interest Income
00000024K000
Interest Expense
2.81M3.69M3.69M4.52M3.3M3.6M5.42M7.29M8.41M8.41M
Other Income/Expense
-2.45M-4.26M-2.11M-5.14M-3.61M-2.1M365K-9.18M-7.56M-7.83M
Pretax Income
-16.06M▲ 0%
-24.1M▼ 50.1%
-29.04M▼ 20.5%
-27.45M▲ 5.5%
-31.17M▼ 13.6%
-37.21M▼ 19.4%
-30.19M▲ 18.9%
-43.74M▼ 44.9%
-39M▲ 10.8%
-37.25M▲ 0%
Pretax Margin %
-39.72%-45.66%-46.35%-55.75%-56.36%-57.06%-42.31%-58.41%-26.15%-24.56%
Income Tax
000000-24K-14K00
Effective Tax Rate %
0%0%0%0%0%0%0.08%0.03%0%0%
Net Income
-16.06M▲ 0%
-24.1M▼ 50.1%
-29.04M▼ 20.5%
-27.45M▲ 5.5%
-31.19M▼ 13.6%
-37.16M▼ 19.1%
-30.19M▲ 18.8%
-43.71M▼ 44.8%
-39M▲ 10.8%
-37.11M▲ 0%
Net Margin %
-39.72%-45.66%-46.35%-55.75%-56.39%-56.99%-42.31%-58.36%-26.15%-24.48%
Net Income Growth %
-42.95%-50.05%-20.53%5.48%-13.62%-19.13%18.76%-44.78%10.78%23.49%
Net Income (Continuing)
-16.06M-24.1M-29.04M-27.45M-31.17M-37.21M-30.16M-43.73M-39M-37.25M
Discontinued Operations
0000000000
Minority Interest
00000004.09M3.86M3.79M
EPS (Diluted)
-1431.28▲ 0%
-2.69▲ 99.8%
-1.87▲ 30.5%
-1.46▲ 21.9%
-1.22▲ 16.4%
-1.38▼ 13.1%
-1.05▲ 23.9%
-1.38▼ 31.4%
-0.59▲ 57.2%
-0.53▲ 0%
EPS Growth %
-42.95%99.81%30.48%21.93%16.44%-13.11%23.91%-31.43%57.25%58.78%
EPS (Basic)
-1431.28-2.69-1.87-1.46-1.22-1.38-1.05-1.38-0.59-
Diluted Shares Outstanding
11.22K8.95M18.38M18.84M25.48M26.9M28.66M31.73M65.95M69.59M
Basic Shares Outstanding
11.22K8.95M18.38M18.84M25.48M26.9M28.66M31.73M65.95M69.59M
Dividend Payout Ratio
----------

STIM Balance Sheet

Neuronetics, Inc. (STIM) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
37.01M114.47M88.45M65.01M115.33M98.77M93.79M58.12M61.55M47.17M
Cash & Short-Term Investments
29.15M104.58M76.59M50.84M96.34M71.88M60.58M19.66M34.36M13.21M
Cash Only
29.15M104.58M75.71M48.96M94.14M70.34M59.68M19.46M34.13M13.21M
Short-Term Investments
00880K1.89M2.2M1.54M905K206K225K0
Accounts Receivable
4.27M5.62M6.57M7.17M7.78M13.82M17.84M24.29M16.89M16.21M
Days Sales Outstanding
38.5238.8738.2753.1151.3477.3691.26118.3641.3447.5
Inventory
2.47M2.43M2.77M3.72M6.56M8.9M8.09M4.25M4.33M4.71M
Days Inventory Outstanding
93.5271.3265.82117.52205.57209.79150.3874.820.5521.17
Other Current Assets
1.12M1.84M1.83M2.19M3.09M2.17M4.77M6.85M5.97M13.04M
Total Non-Current Assets
1.93M2.55M11.72M13.64M25.89M18.11M22.04M82.78M80M78.27M
Property, Plant & Equipment
1.36M1.38M4.9M4.15M5.1M5.32M4.78M33.34M28.03M26.94M
Fixed Asset Turnover
29.75x38.30x12.78x11.87x10.84x12.26x14.92x2.25x5.32x5.32x
Goodwill
000000018.63M23.62M23.62M
Intangible Assets
400K1M0000019.61M18.15M17.79M
Long-Term Investments
001.73M2.33M1.7M1.22M661K86K249K775K
Other Non-Current Assets
174K171K5.08M7.17M19.09M11.57M16.59M11.12M9.95M9.81M
Total Assets
38.94M▲ 0%
117.02M▲ 200.5%
100.17M▼ 14.4%
78.66M▼ 21.5%
141.22M▲ 79.5%
116.88M▼ 17.2%
115.83M▼ 0.9%
140.9M▲ 21.6%
141.55M▲ 0.5%
125.44M▲ 0%
Asset Turnover
1.04x0.45x0.63x0.63x0.39x0.56x0.62x0.53x1.05x1.11x
Asset Growth %
57.02%200.53%-14.4%-21.47%79.54%-17.23%-0.9%21.65%0.46%124.15%
Total Current Liabilities
11.99M13.56M27.69M13.68M15.7M33.2M19.81M31.27M30.52M28.29M
Accounts Payable
2.51M3.76M4.63M3.75M4.3M2.43M4.75M11.08M10.74M11.43M
Days Payables Outstanding
95.23110.14109.7118.43134.6657.3688.3195.0551.0150.27
Short-Term Debt
0011.25M0013.13M005.56M5.42M
Deferred Revenue (Current)
1.97M2.25M2.23M2.02M2.5M1.98M1.62M974K753K3.23M
Other Current Liabilities
2.72M2.64M5.72M5.02M5.09M11.2M8M8.95M13.47M10.6M
Current Ratio
3.09x8.44x3.19x4.75x7.34x2.98x4.73x1.86x2.02x1.67x
Quick Ratio
2.88x8.26x3.09x4.48x6.93x2.71x4.33x1.72x1.87x1.50x
Cash Conversion Cycle
36.810.04-5.6152.2122.25229.8153.34-1.8910.8818.4
Total Non-Current Liabilities
219.6M32.42M24.62M39.48M40.34M26.63M61.83M77.84M84.79M80.09M
Long-Term Debt
29.56M30.39M19.9M34.62M35.34M22.83M59.28M55.15M65.81M18.67M
Capital Lease Obligations
002.62M3.12M3.54M2.97M2.35M22.69M18.93M58.23M
Deferred Tax Liabilities
0000000000
Other Non-Current Liabilities
187.76M86K000000061.43M
Total Liabilities
231.59M45.98M52.32M53.16M56.05M59.82M81.64M109.1M115.31M108.38M
Total Debt
29.56M30.39M34.33M38.34M39.54M39.74M62.47M82.63M90.3M24.09M
Net Debt
409K-74.19M-41.38M-10.62M-54.6M-30.59M2.8M63.17M56.17M10.88M
Debt / Equity
-0.43x0.72x1.50x0.46x0.70x1.83x2.60x3.44x1.41x
Debt / EBITDA
----------0.90x
Net Debt / EBITDA
----------0.40x
Interest Coverage
-4.72x-5.53x-7.67x-5.93x-8.45x-9.34x-4.57x-5.00x-3.74x-2.43x
Total Equity
-192.65M▲ 0%
71.04M▲ 136.9%
47.85M▼ 32.6%
25.49M▼ 46.7%
85.17M▲ 234.1%
57.06M▼ 33.0%
34.19M▼ 40.1%
31.8M▼ 7.0%
26.24M▼ 17.5%
17.06M▲ 0%
Equity Growth %
-8.77%136.88%-32.64%-46.73%234.11%-33.01%-40.08%-6.99%-17.48%222.49%
Book Value per Share
-17170.417.942.601.353.342.121.191.000.400.25
Total Shareholders' Equity
-192.65M71.04M47.85M25.49M85.17M57.06M34.19M27.71M22.38M13.27M
Common Stock
2K177K186K191K264K273K291K557K690K696K
Retained Earnings
-196.95M-221.04M-250.09M-277.54M-308.73M-345.89M-376.08M-419.79M-458.79M-469.58M
Treasury Stock
0000000000
Accumulated OCI
4.23M000000000
Minority Interest
00000004.09M3.86M3.79M

STIM Cash Flow Statement

Neuronetics, Inc. (STIM) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-11.14M-20.59M-30.48M-28.39M-27.98M-30.74M-32.04M-31M-20.37M-3.38M
Operating CF Margin %
-27.56%-39.02%-48.65%-57.65%-50.59%-47.14%-44.9%-41.39%-13.66%-
Operating CF Growth %
-30.48%-84.77%-48.04%6.86%1.43%-9.85%-4.23%3.25%34.27%325.55%
Net Income
-16.06M-24.1M-29.04M-27.45M-31.19M-37.16M-30.19M-43.73M-39.13M-37.11M
Depreciation & Amortization
596K882K1.06M941K1.06M1.65M2.01M2.07M3.46M2.55M
Stock-Based Compensation
496K1.74M3.43M4.4M7.87M8.75M7.32M5.6M6.85M5.4M
Deferred Taxes
-271K1.4M00000000
Other Non-Cash Items
938K1.07M976K1.99M918K1.14M2.93M11.86M1.87M3.79M
Working Capital Changes
3.16M-1.58M-6.91M-8.28M-6.64M-5.12M-14.1M-6.81M6.58M11.6M
Change in Receivables
-690K-1.35M-950K-597K-3.05M-6.66M-8.83M-3.73M3.54M6.17M
Change in Inventory
-1.07M-435K-306K-945K-3.44M-2.59M-1.1M3.15M-395K-570K
Change in Payables
788K606K299K-1.08M276K-1.97M2.03M-1.99M-1.75M888K
Cash from Investing
-594K-1.01M-813K-730K-9.84M6.73M-1.32M-2.41M-801K-581K
Capital Expenditures
-594K-1.01M-813K-730K-2.35M-3.27M-2.37M-1.47M-801K-582K
CapEx % of Revenue
1.47%1.92%1.3%1.48%4.25%5.01%3.32%1.96%0.54%0.38%
Acquisitions
0000000-2.55M025K
Investments
----------
Other Investing
002.61M0-7.81M10M1.05M1.61M31K11K
Cash from Financing
23.84M97.04M2.42M2.37M83.01M207K22.7M-6.81M35.85M16.87M
Debt Issued (Net)
10M002.5M0023.8M-2.52M9.62M4.62M
Equity Issued (Net)
14.82M100M0080.97M00026.82M7.85M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
-980K-2.96M2.42M-131K2.03M207K-1.1M-4.29M-594K4.41M
Net Change in Cash
12.11M▲ 0%
75.44M▲ 523.1%
-28.88M▼ 138.3%
-26.75M▲ 7.4%
45.18M▲ 268.9%
-23.8M▼ 152.7%
-10.66M▲ 55.2%
-40.22M▼ 277.2%
14.68M▲ 136.5%
-2.26M▲ 0%
Free Cash Flow
-11.74M▲ 0%
-21.6M▼ 84.0%
-31.3M▼ 44.9%
-29.12M▲ 6.9%
-30.34M▼ 4.2%
-34.01M▼ 12.1%
-34.41M▼ 1.2%
-32.46M▲ 5.7%
-21.18M▲ 34.8%
-3.96M▲ 0%
FCF Margin %
-29.03%-40.93%-49.95%-59.13%-54.85%-52.15%-48.22%-43.35%-14.2%-2.61%
FCF Growth %
-32.41%-84.03%-44.87%6.95%-4.18%-12.1%-1.17%5.65%34.77%89.37%
FCF per Share
-1046.17-2.41-1.70-1.55-1.19-1.26-1.20-1.02-0.32-0.06
FCF Conversion (FCF/Net Income)
0.69x0.85x1.05x1.03x0.90x0.83x1.06x0.71x0.52x0.11x
Interest Paid
0003.89M03.54M4.79M6.51M00
Taxes Paid
0000000000

STIM Key Ratios

Neuronetics, Inc. (STIM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
--33.92%-48.86%-74.86%-56.37%-52.25%-66.17%-132.47%-134.39%-139.83%
Return on Invested Capital (ROIC)
---1215.25%-156.8%-90.97%-92.33%-72.23%-39.29%-26.58%-30.15%
Gross Margin
76.18%76.42%75.44%76.54%78.93%76.26%72.47%72.32%48.48%47.96%
Net Margin
-39.72%-45.66%-46.35%-55.75%-56.39%-56.99%-42.31%-58.36%-26.15%-24.48%
Debt / Equity
-0.43x0.72x1.50x0.46x0.70x1.83x2.60x3.44x1.41x
Interest Coverage
-4.72x-5.53x-7.67x-5.93x-8.45x-9.34x-4.57x-5.00x-3.74x-2.43x
FCF Conversion
0.69x0.85x1.05x1.03x0.90x0.83x1.06x0.71x0.52x0.11x
Revenue Growth
18.13%30.53%18.72%-21.41%12.32%17.89%9.42%4.96%99.17%69.52%
Related:STIM Dividend History·STIM Revenue History·STIM Price History·STIM P/E History·STIM Financial Ratios·STIM Institutional Holders

STIM SEC Filings & Documents

Neuronetics, Inc. (STIM) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 5, 2026·SEC

Material company update

Apr 6, 2026·SEC

Material company update

Mar 17, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 17, 2026·SEC

FY 2025

Mar 27, 2025·SEC

FY 2024

Mar 8, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 5, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 5, 2025·SEC

STIM Frequently Asked Questions

Neuronetics, Inc. (STIM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Neuronetics, Inc. (STIM) reported $151.6M in revenue for fiscal year 2025. This represents a 343% increase from $34.2M in 2016.

Neuronetics, Inc. (STIM) grew revenue by 99.2% over the past year. This is strong growth.

Neuronetics, Inc. (STIM) reported a net loss of $37.1M for fiscal year 2025.

Dividend & Returns

Neuronetics, Inc. (STIM) has a return on equity (ROE) of -134.4%. Negative ROE indicates the company is unprofitable.

Neuronetics, Inc. (STIM) had negative free cash flow of $4.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in STIM back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →

How much would $100/month in STIM be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →